Citations

Clear

3942 citation(s) found for "To, Van".

Impaired Myocardial Oxygen Availability Contributes to Abnormal Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction
Empel, Vanessa van , Mariani, Justin A. , Borlaug, Barry A. , Kaye, David M. , Borlaug, Barry A , Kaye, David M

Mayo Clinic

Journal of the American Heart Association | December 3, 2014 | Volume: 3 | Issue: 6 | Pages: No page available

10.1161/jaha.114.001293 | PMID 25468660 Get It

Background Hypertension is a frequent risk factor for the development of heart failure with preserved ejection fraction ( HFPEF ). Progressive extracellular matrix accumulation has been presumed to be the fundamental pathophysiologic mechanism that leads to the transition to impaired diastolic reserve. However, the contribution of other mechanisms affecting active and passive components of diastolic function has not been comprehensively assessed. In this study, we investigated the potential role of impaired myocardial oxygen delivery in the pathophysiology of HFPEF . Methods and Results Patients with HFPEF , those with controlled hypertension, and healthy controls underwent simultaneous right‐heart catheterization, echocardiography, and paired arterial and coronary sinus blood gas sampling at rest and during supine‐cycle ergometry. Despite a lower workload ( HFPEF vs control, hypertension: 43±8 versus 114±12, 87±14 W; P <0.001 and P <0.05, respectively), peak exercise pulmonary capillary wedge pressure was markedly higher in HFPEF patients compared with healthy and hypertensive controls (32±2 versus 16±1 and 17±1 mm Hg, both P <0.001). During exercise, the transcardiac oxygen gradient increased significantly in all groups; however, the peak transcardiac oxygen gradient was significantly lower in HFPEF patients ( P <0.05). In addition, the left ventricular–work corrected transcardiac oxygen gradient remained significantly lower in HFPEF patients compared with controls ( P <0.001). Conclusion The current study provides unique data suggesting that the abnormal diastolic reserve observed during exertion in HFPEF patients may, in part, be explained by impaired myocardial oxygen delivery due possibly to microvascular dysfunction. Further studies are required to confirm the structural and functional basis of these findings and to investigate the influence of potential therapies on this abnormality.
α 2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction
Peng, Yin, Che, Pulin , Gannon, Mary , Liu, Yin , Li, Ling , Bu, Guojun , Groen, Thomas van , Jiao, Kai , Wang, Qin , Chen, Yunjia , Peng, Yin, Bu, Guojun

Mayo Clinic

Proceedings of the National Academy of Sciences | November 20, 2014 | Volume: 111 | Issue: 48 | Pages: 17296-17301

10.1073/pnas.1409513111 | PMID 25404298 Get It

Significance Endocytic sorting of amyloid precursor protein (APP) governed by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and the generation of amyloid β (Aβ) peptides, the key pathogenic factor of Alzheimer's disease (AD). This study provides the first evidence to our knowledge that a G protein-coupled receptor, namely, the α 2A adrenergic receptor, modulates APP endocytic sorting and promotes Aβ generation through disrupting APP interaction with a Vps10 family protein, sorting-related receptor with A repeat. Significantly, blockade of α 2A AR by a clinical antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting repurposing clinical α 2 AR antagonists as a new direction for AD treatment.
The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Sanda, Martin G. , Broyles, Dennis L., Shin, Sanghyuk S. , Bangma, Chris H. , Wei, John T., Partin, Alan W. , Klee, George G., Slawin, Kevin M., Marks, Leonard S. , Schaik, Ron H. N. van , Chan, Daniel W. , Sokoll, Lori J. , Cruz, Amabelle B., Mizrahi, Isaac, Catàlona, William J. , Loeb, Stacy

Mayo Clinic

Journal of Urology | November 17, 2014 | Volume: 193 | Issue: 4 | Pages: 1163-1169

10.1016/j.juro.2014.10.121 | PMID 25463993 Get It

Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Databas
Shi, Qian , Gramont, Aimery de , Grothey, Axel, Zalcberg, John , Chibaudel, Benoist , Seymour, Michel , Adams, Richard , Saltz, Leonard B. , Goldberg, Richard M. , Punt, Cornelis J.A. , Douillard, Jean‐Yves , Hoff, Paulo M. , Hecht, J. Randolph, Hurwitz, Herbert I. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Fuchs, Charles S. , Souglakos, John , Falcone, Alfredo , Tournigand, Christophe , Kabbinavar, Fairooz F. , Heinemann, Volker , Bokemeyer, Carsten , de Gramont, Aimery, Schmoll, Hans‐Joachim , Seymour, Matthew T, Saltz, Leonard, Hecht, Joel Randolph, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, Buyse, Marc , Cutsem, Eric Van , Sargent, Daniel J. , Saltz, Leonard , Shi, Qian , Falcone, Alfredo , Seymour, Matthew T , Zalcberg, John , Adams, Richard , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | November 11, 2014 | Volume: 33 | Issue: 1 | Pages: 22-28

10.1200/jco.2014.56.5887 | PMID 25385741 Get It

PurposeProgression-free survival (PFS) has previously been established as a surrogate for overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC treatment has advanced in the last decade with extended OS, this surrogacy requires re-examination.MethodsIndividual patient data from 16,762 patients were available from 22 first-line mCRC studies conducted from 1997 to 2006; 12 of those studies tested antiangiogenic and/or anti–epidermal growth factor receptor agents. The relationship between PFS (first event of progression or death) and OS was evaluated by using R2statistics (the closer the value is to 1, the stronger the correlation) from weighted least squares regression of trial-specific hazard ratios estimated by using Cox and Copula models.ResultsForty-four percent of patients received a regimen that included biologic agents. Median first-line PFS was 8.3 months, and median OS was 18.2 months. The correlation between PFS and OS was modest (R2, 0.45 to 0.69). Analyses limited to trials that tested treatments with biologic agents, nonstrategy trials, or superiority trials did not improve surrogacy.ConclusionIn modern mCRC trials, in which survival after the first progression exceeds time to first progression, a positive but modest correlation was observed between OS and PFS at both the patient and trial levels. This finding demonstrates the substantial variability in OS introduced by the number of lines of therapy and types of effective subsequent treatments and the associated challenge to the use of OS as an end point to assess the benefit attributable to a single line of therapy. PFS remains an appropriate primary end point for first-line mCRC trials to detect the direct treatment effect of new agents.
Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia
Ojha, Juhi, Secreto, Charla, Rabe, Kari G. , Dyke, Daniel L. Van , Braggio, Esteban , Kortüm, K. Martin , Slager, Susan L. , Shanafelt, Tait D. , Fonseca, Rafaël , Kay, Neil E. , Chaffee, Kari G. , Braggio, Esteban

Mayo Clinic

British Journal of Haematology | November 10, 2014 | Volume: 169 | Issue: 3 | Pages: 445-448

10.1111/bjh.13211 | PMID 25382417 Get It

The Rare Cancer Network: Ongoing Studies and Future Strategy
Özşahin, Mahmut , Mirimanoff, René-Olivier, Thariat, Juliette , Sun, Xu , Atalar, Banu , Lassen–Ramshad, Yasmin , Uğurluer, Gamze , Hallemeier, Christopher L. , Houtte, Paul Van , Krengli, Marco , Zhang, Lan Jun, Funk, Ryan K., Rooney, Jessica, Miller, Robert C. , Hallemeier, Christopher, Chang, Kenneth , Funk, Ryan, Mirimanoff, R.O., Krishnan, Sunil , Hallemeier, Christopher Leigh , Chang, Kenneth Tou En , Thariat, Juliette

Mayo Clinic

Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 91-94

10.4081/rt.2014.5465 | PMID 25276326 Get It

The Rare Cancer Network (RCN) was formed in the early 1990's to create a global network that could pool knowledge and resources in the studies of rare malignancies whose infrequency prevented both their study with prospective clinical trials. To date, the RCN has initiated 74 studies resulting in 46 peer reviewed publications. The First International Symposium of the Rare Cancer Network took place in Nice in March of 2014. Status updates and proposals for new studies were heard for fifteen topics. Ongoing studies continue for cardiac sarcomas, thyroid cancers, glomus tumors, and adult medulloblastomas. New proposals were presented at the symposium for primary hepatic lymphoma, solitary fibrous tumors, Rosai-Dorfman disease, tumors of the ampulla of Vater, salivary gland tumors, anorectal melanoma, midline nuclear protein in testes carcinoma, pulmonary lymphoepithelioma-like carcinoma, adenoid cystic carcinoma of the trachea, osteosarcomas of the mandible, and extra-cranial hemangiopericytoma. This manuscript presents the abstracts of those proposals and updates on ongoing studies, as well a brief summary of the vision and future of the RCN.
Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia
Ojha, Juhi, Ayres-Silva, Jackline de Paula , Secreto, Charla, Tschumper, Renee C. , Rabe, Kari G. , Dyke, Daniel Van, Braggio, Esteban , Tschumper, Renee, Rabe, Kari, Van Dyke, Daniel, Slager, Susan, Dyke, Daniel L. Van , Slager, Susan L. , Shanafelt, Tait D. , Fonseca, Rafaël , Kay, Neil E. , Chaffee, Kari G. , Braggio, Esteban

Mayo Clinic

Blood | November 6, 2014 | Volume: 125 | Issue: 3 | Pages: 492-498

10.1182/blood-2014-06-580563 | PMID 25377784 Get It

Key Points Deep sequencing identifies a significant reservoir of subclonal mutations affecting key genes in CLL pathogenesis. Convergent evolution of genetic lesions in tumor subclonal populations is recurrently found in CLL.
COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A
Phillips-Krawczak, Christine, Singla, Amika , Starokadomskyy, Petro , Deng, Zhi-Hui , Osborne, Douglas G. , Li, Haiying , Dick, Christopher J., Gomez, Timothy S., Koenecke, Megan M, Zhang, Jin‐San , Dai, Haiming , Sifuentes-Dominguez, Luis , Geng, Linda N. , Hein, Marco Y. , Wallis, Mathew , McGaughran, Julie , Gécz, Jozef , Sluis, Bart van de , Billadeau, Daniel D. , Burstein, Ezra , Kaufmann, Scott H. , van de Sluis, Bart , Burstein, Ezra , McGaughran, Julie , Wallis, Mathew , Dai, Haiming , Geng, Linda N.

Mayo Clinic

Molecular Biology of the Cell | October 30, 2014 | Volume: 26 | Issue: 1 | Pages: 91-103

10.1091/mbc.e14-06-1073 | PMID 25355947 Get It

COMMD1 deficiency results in defective copper homeostasis, but the mechanism for this has remained elusive. Here we report that COMMD1 is directly linked to early endosomes through its interaction with a protein complex containing CCDC22, CCDC93, and C16orf62. This COMMD/CCDC22/CCDC93 (CCC) complex interacts with the multisubunit WASH complex, an evolutionarily conserved system, which is required for endosomal deposition of F-actin and cargo trafficking in conjunction with the retromer. Interactions between the WASH complex subunit FAM21, and the carboxyl-terminal ends of CCDC22 and CCDC93 are responsible for CCC complex recruitment to endosomes. We show that depletion of CCC complex components leads to lack of copper-dependent movement of the copper transporter ATP7A from endosomes, resulting in intracellular copper accumulation and modest alterations in copper homeostasis in humans with CCDC22 mutations. This work provides a mechanistic explanation for the role of COMMD1 in copper homeostasis and uncovers additional genes involved in the regulation of copper transporter recycling.
Biological Strategies for Improved Osseointegration and Osteoinduction of Porous Metal Orthopedic Implants
Lewallen, Eric A. , Riester, Scott M. , Kremers, Hilal Maradit , Dudakovic, Amel , Cohen, Robert C., Lewallen, David G. , Wijnen, André J. van , Lewallen, Eric Alexander, Bonin, Carolina A. , Kakar, Sanjeev , Westendorf, Jennifer J. , van Wijnen, Andre J , Maradit Kremers, Hilal

Mayo Clinic

Tissue Engineering Part B: Reviews | October 27, 2014 | Volume: 21 | Issue: 2 | Pages: 218-230

10.1089/ten.teb.2014.0333 | PMID 25348836 Get It

The biological interface between an orthopedic implant and the surrounding host tissue may have a dramatic effect upon clinical outcome. Desired effects include bony ingrowth (osseointegration), stimulation of osteogenesis (osteoinduction), increased vascularization, and improved mechanical stability. Implant loosening, fibrous encapsulation, corrosion, infection, and inflammation, as well as physical mismatch may have deleterious clinical effects. This is particularly true of implants used in the reconstruction of load-bearing synovial joints such as the knee, hip, and the shoulder. The surfaces of orthopedic implants have evolved from solid-smooth to roughened-coarse and most recently, to porous in an effort to create a three-dimensional architecture for bone apposition and osseointegration. Total joint surgeries are increasingly performed in younger individuals with a longer life expectancy, and therefore, the postimplantation lifespan of devices must increase commensurately. This review discusses advancements in biomaterials science and cell-based therapies that may further improve orthopedic success rates. We focus on material and biological properties of orthopedic implants fabricated from porous metal and highlight some relevant developments in stem-cell research. We posit that the ideal primary and revision orthopedic load-bearing metal implants are highly porous and may be chemically modified to induce stem cell growth and osteogenic differentiation, while minimizing inflammation and infection. We conclude that integration of new biological, chemical, and mechanical methods is likely to yield more effective strategies to control and modify the implant–bone interface and thereby improve long-term clinical outcomes.